SCHEMBL17397207

SCHEMBL17397207

CC(=O)c1cc2cccc(C)n2c(=O)c1-c1cccc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.37
PIK3CD O00329 7/20 0.37
TRPM8 Q7Z2W7 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NOTUM Q6P988 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TGFBR1 P36897 1/20 0.35
PDE4B Q07343 1/20 0.34
DHODH Q02127 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
RIPK1 Q13546 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17397188 0.87 PIK3CD (0.41) PIK3CDKDM4EALDH1A1KMT2ACYP2C9
SCHEMBL25210629 0.80 PIK3CD (0.41) PIK3CDTRPM8KDM4EALDH1A1PDE4B
SCHEMBL17397109 0.79 PIK3CD (0.43) PTGS2PIK3CDTGFBR1CYP3A4CYP2D6
SCHEMBL17397300 0.78 PIK3CD (0.42) PIK3CDKDM4ENOTUMALDH1A1PIK3CA
SCHEMBL17397113 0.77 PIK3CD (0.45) PTGS2PIK3CDTGFBR1PIK3CAPIK3CB
SCHEMBL17397181 0.74 KDM4E (0.39) KDM4EALDH1A1KMT2ARXFP1
SCHEMBL25206655 0.74 TRPM8 (0.36) PTGS2PIK3CDTRPM8KDM4EALDH1A1
SCHEMBL17397262 0.72 KDM4E (0.55) KDM4EALDH1A1KMT2A
SCHEMBL3907815 0.71 TRPM8 (0.43) TRPM8ALDH1A1KMT2ADHODH
SCHEMBL25251706 0.70 PIK3CD (0.41) PIK3CDKDM4ENOTUMALDH1A1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
EP-3164400-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS Lupin Limited (IN) 2017-05-10 EP disclosed
WO-2016001855-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2016-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS PIK3R5, PIK3R1, PIK3R4 PTGS2 1573/4885PIK3CD 5/4885TRPM8 4559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.